Zhou Jiang-Tao, Li Cai-Lan, Tan Li-Hua, Xu Yi-Fei, Liu Yu-Hong, Mo Zhi-Zhun, Dou Yao-Xing, Su Rui, Su Zi-Ren, Huang Ping, Xie Jian-Hui
Guangdong Provincial Key Laboratory of New Drug Development and Research of Chinese Medicine, School of Chinese Materia Medica, Guangzhou University of Chinese Medicine, Guangzhou, PR China.
The First Affiliated Hospital of Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou, PR China.
PLoS One. 2017 Jan 3;12(1):e0168944. doi: 10.1371/journal.pone.0168944. eCollection 2017.
In this paper, we evaluated the anti-Helicobacter pylori activity and the possible inhibitory effect on its associated urease by Palmatine (Pal) from Coptis chinensis, and explored the potential underlying mechanism. Results indicated that Pal exerted inhibitory effect on four tested H. pylori strains (ATCC 43504, NCTC 26695, SS1 and ICDC 111001) by the agar dilution test with minimum inhibitory concentration (MIC) values ranging from 100 to 200 μg/mL under neutral environment (pH 7.4), and from 75 to 100 μg/mL under acidic conditions (pH 5.3), respectively. Pal was observed to significantly inhibit both H. pylori urease (HPU) and jack bean urease (JBU) in a dose-dependent manner, with IC50 values of 0.53 ± 0.01 mM and 0.03 ± 0.00 mM, respectively, as compared with acetohydroxamic acid, a well-known urease inhibitor (0.07 ± 0.01 mM for HPU and 0.02 ± 0.00 mM for JBU, respectively). Kinetic analyses showed that the type of urease inhibition by Pal was noncompetitive for both HPU and JBU. Higher effectiveness of thiol protectors against urease inhibition than the competitive Ni2+ binding inhibitors was observed, indicating the essential role of the active-site sulfhydryl group in the urease inhibition by Pal. DTT reactivation assay indicated that the inhibition on the two ureases was reversible, further supporting that sulfhydryl group should be obligatory for urease inhibition by Pal. Furthermore, molecular docking study indicated that Pal interacted with the important sulfhydryl groups and inhibited the active enzymatic conformation through N-H ∙ π interaction, but did not interact with the active site Ni2+. Taken together, Pal was an effective inhibitor of H. pylori and its urease targeting the sulfhydryl groups, representing a promising candidate as novel urease inhibitor. This investigation also gave additional scientific support to the use of C. chinensis to treat H. pylori-related gastrointestinal diseases in traditional Chinese medicine. Pal might be a potentially beneficial therapy for gastritis and peptic ulcers induced by H. pylori infection and other urease-related diseases.
在本文中,我们评估了黄连中的巴马汀(Pal)对幽门螺杆菌的抗菌活性及其对幽门螺杆菌相关脲酶的潜在抑制作用,并探讨了其潜在的作用机制。结果表明,通过琼脂稀释试验,Pal对四种受试幽门螺杆菌菌株(ATCC 43504、NCTC 26695、SS1和ICDC 111001)具有抑制作用,在中性环境(pH 7.4)下的最低抑菌浓度(MIC)值为100至200 μg/mL,在酸性条件(pH 5.3)下为75至100 μg/mL。观察到Pal以剂量依赖性方式显著抑制幽门螺杆菌脲酶(HPU)和刀豆脲酶(JBU),IC50值分别为0.53±0.01 mM和0.03±0.00 mM,而著名的脲酶抑制剂乙酰氧肟酸的IC50值分别为0.07±0.01 mM(HPU)和0.02±0.00 mM(JBU)。动力学分析表明,Pal对HPU和JBU的脲酶抑制类型均为非竞争性。观察到巯基保护剂对脲酶抑制的效果高于竞争性Ni2+结合抑制剂,表明活性位点巯基在Pal对脲酶的抑制中起重要作用。二硫苏糖醇(DTT)再激活试验表明,对两种脲酶的抑制是可逆的,进一步支持了巯基是Pal抑制脲酶所必需的。此外,分子对接研究表明,Pal与重要的巯基相互作用,并通过N-H∙∙π相互作用抑制活性酶构象,但不与活性位点Ni2+相互作用。综上所述,Pal是一种针对巯基的幽门螺杆菌及其脲酶的有效抑制剂,是一种有前途的新型脲酶抑制剂候选物。本研究也为中药黄连用于治疗幽门螺杆菌相关胃肠道疾病提供了更多科学依据。Pal可能是治疗幽门螺杆菌感染引起的胃炎和消化性溃疡以及其他脲酶相关疾病的潜在有益疗法。